BIOMAT Database Logo BIOMAT Database Logo

Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B. 1996

A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Riley Hospital for Children, Indiana University Medical Center, Indianapolis 46202-5225, USA.

The safety and efficacy of a monoclonal antibody purified factor IX concentrate were evaluated in two continuing trials of 32 previously untreated patients with mild, moderate, or severe hemophilia B. Patients were evaluated every 2 weeks for 24 weeks and every 3 months thereafter for at least 1 year. No patients became positive for human immunodeficiency virus antibody or hepatitis C virus antibody during the trial. Two patients developed a false-positive hepatitis B core antibody, one transiently, but neither had elevated levels of alanine aminotransferase (ALT). None of the 25 patients evaluable for non-A, non-B, non-C hepatitis by strict International Society of Thrombosis and Hemostasis criteria developed elevated levels of ALT indicative of posttransfusion infection. Anaphylaxis occurred in one subject who also developed an inhibitor to factor IX (19.3 Bethesda units). Five of the eight adverse events reported (63%) were mild in severity, and the relationship of three of these to therapy was considered remote. Hemostasis with monoclonal antibody purified factor IX concentrate was excellent in all patients.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002836 Hemophilia B A deficiency of blood coagulation factor IX inherited as an X-linked disorder. (Also known as Christmas Disease, after the first patient studied in detail, not the holy day.) Historical and clinical features resemble those in classic hemophilia (HEMOPHILIA A), but patients present with fewer symptoms. Severity of bleeding is usually similar in members of a single family. Many patients are asymptomatic until the hemostatic system is stressed by surgery or trauma. Treatment is similar to that for hemophilia A. (From Cecil Textbook of Medicine, 19th ed, p1008) Christmas Disease,Factor IX Deficiency,Deficiency, Factor IX,F9 Deficiency,Haemophilia B,Hemophilia B Leyden,Hemophilia B(M),Plasma Thromboplastin Component Deficiency,Bs, Hemophilia,Deficiencies, F9,Deficiencies, Factor IX,Deficiency, F9,Disease, Christmas,F9 Deficiencies,Factor IX Deficiencies,Haemophilia Bs,Hemophilia Bs,Hemophilia Bs (M)
D002846 Chromatography, Affinity A chromatographic technique that utilizes the ability of biological molecules, often ANTIBODIES, to bind to certain ligands specifically and reversibly. It is used in protein biochemistry. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Bioaffinity,Immunochromatography,Affinity Chromatography,Bioaffinity Chromatography
D005069 Evaluation Studies as Topic Works about studies that determine the effectiveness or value of processes, personnel, and equipment, or the material on conducting such studies. Critique,Evaluation Indexes,Evaluation Methodology,Evaluation Report,Evaluation Research,Methodology, Evaluation,Pre-Post Tests,Qualitative Evaluation,Quantitative Evaluation,Theoretical Effectiveness,Use-Effectiveness,Critiques,Effectiveness, Theoretical,Evaluation Methodologies,Evaluation Reports,Evaluation, Qualitative,Evaluation, Quantitative,Evaluations, Qualitative,Evaluations, Quantitative,Indexes, Evaluation,Methodologies, Evaluation,Pre Post Tests,Pre-Post Test,Qualitative Evaluations,Quantitative Evaluations,Report, Evaluation,Reports, Evaluation,Research, Evaluation,Test, Pre-Post,Tests, Pre-Post,Use Effectiveness
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D005260 Female Females

Related Publications

A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures.
October 1997, Haemophilia : the official journal of the World Federation of Hemophilia,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Viral safety of a pasteurized, monoclonal antibody-purified factor VIII concentrate in previously untreated haemophilia A patients.
March 2001, Haemophilia : the official journal of the World Federation of Hemophilia,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
February 1996, American journal of hematology,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
April 1990, Seminars in hematology,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Safety and Efficacy of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Untreated Patients with Hemophilia B.
January 2024, TH open : companion journal to thrombosis and haemostasis,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
December 2002, Blood,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
December 2001, Blood,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
January 2005, Blood,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Monoclonal antibody-purified factor IX--comparative thrombogenicity to prothrombin complex concentrate.
July 1991, Seminars in hematology,
A D Shapiro, and M V Ragni, and J M Lusher, and S Culbert, and M A Koerper, and G E Bergman, and M M Hannan
Lack of immune response to mouse IgG in previously untreated haemophilia A and haemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations.
April 1997, Haemophilia : the official journal of the World Federation of Hemophilia,
Copied contents to your clipboard!